Pectin-honey hydrogel: Characterization, antimicrobial activity and biocompatibility by Giusto, Gessica et al.
 
 
1 
Pectin-honey hydrogel: characterization, antimicrobial activity and biocompatibility 1 
 2 
Gessica Giustoa, Giangiacomo Berettab, Cristina Vercellia, Emanuela Vallea, Selina Iussicha, 3 
Roberta Borghic, Patrizio Odettic, Fiammetta Monacellic, Clara Tramutaa, Elena Gregoa, Patrizia 4 
Nebbiaa, Patrizia Robinoa, Rosangela Odorea, Marco Gandinia 5 
 6 
a Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2-5, 10095 7 
Grugliasco (TO), Italy 8 
b Department of Pharmaceutical Sciences DISFARM, University of Milan, Via Mangiagalli 25, 9 
20133 Milano (MI), Italy 10 
c Department of Internal Medicine and Medical Specialties, University of Genoa, Viale Benedetto 11 
XV 6, 16132 Genova (GE), Italy  12 
 13 
 14 
Address correspondence to Dr. Gandini at marco.gandini@unito.it from the Department of 15 
Veterinary Sciences, University of Turin, Largo Paolo Braccini 2-5, 10095 Grugliasco (TO), 16 
Italy, phone +390116708861 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 
 
2 
Abstract 25 
Background: Novel pectin-honey hydrogels have been developed and characterized as medical 26 
device. Ideally, a wound dressing should maintain optimal fluid affinity, permit moisture 27 
evaporation, protect the wound from microbes, and have shape-conformability, biocompatibility, 28 
and antibacterial activity. Objective: A novel, simple and fast method to produce pectin-honey 29 
wound dressings is described. Methods: The properties of these pectin-honey hydrogels were 30 
investigated, including swelling ability, water vapour transmission rate, hydrogen peroxide 31 
production, methylglyoxal content and antibacterial activity. Biocompatibility was assessed by 32 
proliferation assays using cultured fibroblast cells and by in vivo study with subcutaneous and 33 
intraperitoneal implantation in rats. Results: Hydrogel showed a good water vapour transmission 34 
rate, fluid uptake and were not cytotoxic for fibroblasts. The hydrogel demonstrated good 35 
antibacterial activity toward clinically relevant pathogens, including S. aureus and E. coli. 36 
Biocompatibility was confirmed by the measurement of plasma levels of interleukin (IL)1 beta, 37 
IL-6, tumour necrosis factor (TNF) alpha, and prostaglandin (PG)E2. No histological changes 38 
were observed. Conclusions: The presence of a natural active component, conformability, and 39 
complete resorbability are the main characteristics of this new biocompatible biomaterial that is 40 
well tolerated by the body, possibly improves healing, may be used for surgical complications 41 
prevention, with a simple and inexpensive production process. 42 
 43 
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Introduction 49 
Healing wounds are sites that are easily attacked by bacteria, which leads to the formation of a 50 
biofilm that devitalises tissues [1]. The development of a new wound dressing is a focus area for 51 
many researchers since the dressing can create a barrier against infection while maintaining a 52 
physiological environment in contact with the wound [2-3]. These dressings help to maintain a 53 
moist environment at the wound site, promote tissue healing, and reduce infection, pain, and 54 
costs [1, 4-5]. Antimicrobial agents play an important role in reducing bacterial contamination, 55 
but the resistance of pathogens to these substances has led to a decrease in the efficacy of 56 
antibiotics. Researchers have therefore advised against the use of systemic antimicrobial agents 57 
for the treatment of wounds [1, 6].  58 
Various wound dressings consisting of vegetable fibres, protective films, hydrogels, and hydrogel 59 
enriched with nitrogen oxides are available commercially [1-2, 5, 7]. Hydrogels are reported to be 60 
suitable for use in healing wounds but they have limitations in current use, which include a 61 
requirement for high frequency of application, inactivation by wound fluids, and formation of 62 
eschars [5]. The requirement for a new antimicrobial substance led to revaluation of ancient 63 
remedies, including the use of honey [8-9].  64 
Honey has been used alone or in combination with other compounds for medical use since 65 
ancient times. Honey is a heterogeneous substance, has antimicrobial activity, anti-inflammatory 66 
effects and increase the healing process following skin or peritoneal damage [8, 10]. It contains 67 
high levels of glycine, methionine and proline which are all fundamental for collagen formation 68 
and fibroblast deposition, which are the main factors for wound healing [11]. 69 
Manuka honey, produced in New Zealand, is the most studied honey having antibacterial 70 
properties against major aerobic and anaerobic bacteria species [12-13]. 71 
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Several components are known to contribute antibacterial activity of honey. The osmotic effect of 72 
the sugars in honey and its characteristically acidic pH are known factors hindering bacterial 73 
multiplication. Recently, two components of honey, hydrogen peroxide (H2O2) and 74 
methylglyoxal (MGO), have been identified as effective antibacterials [14-16]. 75 
An ideal wound dressing is yet to be developed. Ideally, a wound dressing should maintain 76 
optimal fluid affinity, permit moisture evaporation, protect the wound from foreign microbes, and 77 
have shape-conformability, biocompatibility, and antibacterial activity [2,4-5,17].   78 
Based on these premises, the aim of the present study was to describe and characterize the 79 
properties of pectin-honey hydrogels (PHHs) for wound healing and to assess their 80 
biocompatibility through an in vitro and in vivo assay.  81 
Material and methods  82 
Materials 83 
Honey was purchased from Manuka Health (66 Weona Court,Te Awamutu 3800, New Zealand) 84 
and pectin from Ardet s.r.l. (Torino, Italy). Culture media, that is, tryptone soy agar (TSA), 85 
tryptone soy broth (TSB), peptone water, and 5% sheep blood agar, were purchased from Oxoid 86 
(Milan, Italy). Escherichia coli (Turin strain) and Staphylococcus aureus (Turin strain) isolated 87 
from canine wounds were used for this work. 88 
Preparation of PHHs 89 
The preparation method was modified after the procedure described by Walker. (Walker, 1942) 90 
[18] Briefly, the pectin-honey hydrogels were prepared starting from a solution (1:1 v/v) of liquid 91 
honey (Manuka Health, New Zealand) and sterile deionized water. The same volume of pectin 92 
powder (ARDET s.r.l., Italy) was then added and with continuous stirring until the mixture was 93 
homogeneous. The resulting gel was spread into 2 mm thick films and hot air dried at 40+/- 0.5 94 
°C for 6 h. Then it was cut into squares of 5 x 5 cm and further conditioned in an air drier at 25+/- 95 
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1 °C for 5 days. The films were then collected and packed in polyethylene under vacuum 96 
conditions. All membranes were sterilized by gamma-irradiation at 25 KGray at the Sterigenics 97 
Italy (Sterigenics Italy, Minerbio (BO), Italy) [19]. 98 
Fluid uptake test (Swelling test) 99 
To investigate the fluid swelling ratio of PHHs, samples were cut into disks with a diameter of 100 
approximately 25 mm. The dry weights (Wdry) of the membranes were measured and recorded. 101 
Afterwards, pre-weighed dry samples were immersed in PBS solution, pH 7.4, at 37°C. The 102 
weights of the swollen PHHs were determined every 5 min subsequently by sandwiching the 103 
membranes between two paper towels to remove excess water on the surface, and then wet 104 
weights (Wwet) were measured. All experiments were performed in triplicate. The swelling 105 
ratios were calculated as the average value according to the following formula:  106 
DS = [(Ww – Wd)/Wd] × 100  107 
Where Ww and Wd represent the weights of wet and dry samples, respectively.  108 
Water vapour transmission rate (WVTR) 109 
The moisture permeability of the PHH was determined by measuring the WVTR. A piece of the 110 
specimen was fixed over the top of a tube (diameter, 34 mm) containing 10 mL PBS. The tube 111 
was then placed in an incubator at 37°C and 35% relative humidity. The membranes were 112 
weighed at regular intervals of time and the weight loss was recorded and plotted on a graph 113 
versus time. The WVTR was calculated from the slope of the graph by the following formula: 114 
WVTR g (m2/day) = (slope × 24)/A 115 
Where A is area of the sample (m2). Experiments were performed in triplicate.  116 
H2O2 analysis 117 
The analysis of H2O2 from honey and PHHs was carried out according to the method reported by 118 
Long (1999) [20] (ferrous ion oxidation-xylenol orange [FOX] assay), with minor modifications. 119 
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The stock reagents were as follows: reagent 1, 4.4 mM butylated hydroxy toluene (BHT) in 120 
HPLC-grade methanol; reagent 2, 1 mM xylenol orange and 2.56 mM ammonium ferrous 121 
sulphate in 250 mM H2SO4; working reagent: one volume of reagent 2 added to nine volumes of 122 
reagent 1. Approximately 200 mg of honey were diluted with deionized water to the ratio 20% 123 
w/w and immediately kept in a thermostat at T = 37 °C, and 100-µL aliquots were added to 900 124 
µl of FOX working reagent. After 20 min of incubation at room temperature, absorbance was 125 
measured at λ= 560 nm against a blank comprising 900 µL of working reagent and 100- µL 126 
aliquots of distilled water (absorbance of diluted honey was negligible at the operative 127 
wavelength). H2O2 was monitored at 5, 10, 15, 20, 30, 60, and 120 min and up to 24 and 48 h of 128 
incubation. 129 
To reduce the processing time required to extract the water-soluble components from PHHs, their 130 
size was reduced prior to incubation by cutting the specimens into small pieces with the aid of a 131 
small and clean knife. Aliquots of 100 µL of the aqueous layer of the final mixture (40% w/w) 132 
were subjected to FOX analysis as described above for honey. Monitoring of H2O2 was carried 133 
out at 60 min, 90 min, 24 h, and 48 h. The FOX assay was calibrated using standard H2O2 134 
(molar extinction coefficient, 43 M-1 cm-1; absorbance wave length of H2O2 λ = 240 nm; linear 135 
range, 0–50 µM). Ten units of catalase were sufficient to destroy all the H2O2 immediately. 136 
Controls with catalase were used to exclude interference due to honey constituents. 137 
Methylglyoxal (MGO) analysis 138 
MGO was evaluated by the method proposed by Wild (2012) [21] with slight modifications. The 139 
method is based on the reaction between N-acetyl-L-cysteine (Sigma Aldrich) and MGO at room 140 
temperature. Samples were diluted in water (340 mg/ml) and the reaction was performed in 100 141 
mM sodium dihydrogen phosphate buffer (adjusted to pH 7.0 with 10 M NaOH) at 22 °C. For the 142 
standard curve of the reaction, different concentrations of MGO (0.5, 1, 2, and 5 mM) were used. 143 
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MGO solutions (Sigma Aldrich) equivalent to 0.5, 2, and 5 mM and 10 µl of each honey solution 144 
(170 mg HBM/ml water) were added up to a volume of 980 µL with sodium dihydrogen 145 
phosphate. The reaction was started by adding 20 µL 500 mM N-acetyl-L-cysteine, and the 146 
absorption was recorded after 7 min. The condensation product, N-α-acetyl-S-(1-hydroxy-2-oxo-147 
prop-1-yl) cysteine, was determined by recording the absorption at 288 nm (UVIKON 923, Bio-148 
Tek Instrument). Results are given in µmol/mg of honey. 149 
Protein content analysis of honeys  150 
Honey samples were diluted in water and the protein content was determined using the BCA 151 
protein assay kit according to the manufacturer’s instructions (Pierce, BCA Protein Assay). 152 
Microbiological analysis 153 
The success of sterilization was verified by the absence of bacterial growth on solid medium (5% 154 
sheep blood agar) at 37 °C for 24 h, both in aerobiosis and anaerobiosis. Subsequently, the 155 
antibacterial activity of PHHs was determined against S. aureus and E. coli, which had been 156 
previously isolated from canine wound infections. The agar good diffusion method was used to 157 
screen the antimicrobial activity of the Manuka PHHs [22]. Clinical strains were grown overnight 158 
in TSB at 37°C and adjusted to 0.5 McFarland standard. Each culture was inoculated on the 159 
surface of Petri plates. Subsequently, wells with 6-mm diameter were bored into the surface of 160 
the agar. The wells were filled with 6 mm of a Manuka honey-based patch, 80 µl of a Manuka 161 
honey sample 100% v/v (as positive control), 80 µl of a Manuka honey sample 50% v/v (as a 162 
positive control that resembles the concentration of honey present in PHHs), and 6 mm of pectin 163 
(as negative control). Plates were incubated at 37°C, and after 24 h, the diameters of the 164 
inhibition zones were measured. Each assay was carried out in triplicate.  165 
In vitro cytotoxicity assay  166 
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The cytocompatibility of PHHs was evaluated using L929 cells (mice fibroblasts) (ECACC Cell 167 
Lines-Sigma Aldrich, Milan, Italy) that were cultured in 75 mL flasks containing Modified 168 
Eagles Medium (MEM; Sigma Aldrich, Milan, Italy), 10% fetal bovine serum (FBS; Sigma 169 
Aldrich, Milan, Italy), 2% L-glutamine (Sigma Aldrich, Milan, Italy), and 2% penicillin-170 
streptomicin-amphotericin B solution (Sigma Aldrich) at 37°C with 5% CO2, 95% air, and 171 
complete humidity. When a confluence of 80% was reached, cells were detached using 0.1% 172 
trypsin/EDTA solution (Sigma Aldrich, Milan, Italy), centrifuged, and counted using Trypan 173 
Blue solution (Sigma Aldrich) with a Burker chamber. Cells were either resuspended at a 174 
concentration of 5×105 cells/mL or stored at -80°C for further analysis. The 3-(4,5-175 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay, a routine method 176 
for quantifying cell viability, was used [23]. 177 
Cells (5×105 cells/100 µL) were transferred into 96-well plates in order to perform the MTT 178 
assay at 24, 48, and 72 hours after seeding. After an overnight incubation at 37°C and 5% CO2, 179 
the medium was changed (MEM, FBS 10%, antibiotic and antimycotic solution 2%, L-glutamine 180 
2%), and serial decreasing concentrations of honey membranes dissolved in phosphate buffered 181 
saline (PBS) solution, starting from 0.1 g/ml, were added. After adding MTT (Sigma Aldrich, 182 
Milan, Italy) solution (4 mg/ml in PBS), the plates were incubated at 37 °C and 5% CO2 for 4 183 
hours. At the end of incubation, the medium was removed, and 100 µL of dimethyl sulfoxide 184 
(DMSO; Sigma Aldrich, Milan, Italy) was added in order to lysate the formazan crystals. The 185 
plates were further incubated for 10 minutes on a continuous shaker at room temperature, and the 186 
optical density of the wells was determined using a plate reader (Poverwave x; Bio-Tek 187 
Instruments Inc., Winooski, USA) at a wavelength of 570 nm. 188 
In vivo biocompatibility study 189 
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All procedures were approved by the Bioethical Committee of the University of Turin and by the 190 
Italian Ministry of Health (protocol number 304/2015-PR, 20/04/2015).  191 
A total of 39 adult male Sprague-Dawley rats, weighing 225-250 grams, were purchased by 192 
Harlan Laboratories (Italy). All rats were housed in single cages for 7 days prior to the beginning 193 
of the experiment. The room temperature was set at 23°C throughout the duration of the 194 
experiment and cages were cleaned daily. Animals were fed with a commercial diet and water 195 
was given ad libitum. Anaesthesia was induced by administering 5 mg/kg of xylazine 196 
(Rompum®, Bayer Animal Health, Italy) and 50 mg/kg of tiletamine and zolazepam (Zoletil 50, 197 
Virbac, Italy) intramuscularly. Anaesthesia lasted for approximately 1 hour. Under anaesthesia, 198 
blood samples were collected from the caudal vein to perform biochemical analysis. Soon after, 199 
the ventral hair was shaved and the skin was prepared using a 3-step iodopovidone – 200 
chlorhexidine scrub. The animals were randomly assigned to the treatment or control groups. A 201 
4-cm midline incision was made in the abdominal wall. In the treatment group, subcutaneous and 202 
intraperitoneal implantation of PHH was performed as previously described [24]. Briefly, one 203 
square each of PHH measuring 1 × 1 cm was implanted intraperitoneally under the left 204 
abdominal wall and subcutaneously at ~1 cm left to the midline between the muscle and skin. In 205 
the control group, only the surgical procedure was performed without PHH implantation. In both 206 
groups, the midline incision was closed in two layers, with 3-0 USP glycomer 631 for the fascia, 207 
and with 3-0 USP nylon for the skin. Each surgical procedure lasted about ~20 minutes.  208 
Blood samples for the biochemical analysis were collected from the caudal vein. The blood was 209 
collected into tubes before surgery and at 6 h (T6), 24 h (T24), and 72 h (T72) post-surgery and at 210 
the time of euthanasia. Plasma levels of IL-1β, IL-6, TNF-α and PG(E2) were measured by using 211 
a commercial ELISA kit (Rat IL1 beta ELISA kit, Booster Biological Technology; Rat Il-6 212 
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ELISA, AB Frontier; Rat TNF alpha ELISA, AB Frontier; Prostaglandin E2 Express EIA kit, 213 
Cayman Chemical).    214 
At 0, 6, 24, 72 hour’s post-surgery, three rats from each group were euthanized and target organs 215 
(liver, kidney, left abdominal wall) were collected and fixed in 4% formaldehyde. These tissues 216 
were sectioned, stained in H&E, and observed by two pathologists in a blinded manner [24]. 217 
Statistical analysis  218 
Normality of the data was evaluated using the Shapiro–Wilk normality test. For the in vitro 219 
cytotoxicity assay, all experiments were performed in triplicate, and the data are representative of 220 
at least three independent experiments. The results, expressed as mean ± SEM values, were 221 
analysed using the Kruskal-Wallis test and a Dunn’s post-test.  222 
For plasma cytokine levels, all experiments were performed in duplicate. For IL-1β, IL-6, and 223 
TNF-α, the results have been expressed as median (95% IC) values and were analysed using the 224 
one-way ANOVA test. For PG(E2), the results are expressed as median (95% IC) and were 225 
analysed using the Friedman test. Statistical analysis was performed with the GraphPad Prism 226 
6.01 software. Values with p < 0.05 were considered significant. 227 
Results 228 
Fluid uptake test (swelling test) 229 
The weight of PHHs immersed in PBS solution under physiological mimicking conditions (pH 230 
7.4, 37°C). The fluid content increased to about 150% after 180 minutes. The results from the 231 
fluid uptake experiment revealed that the dressing has wide capacity to prevent fluid 232 
accumulation if used on wound.  233 
WVTR 234 
The transmission of water vapour through the membranes is an important parameter for the 235 
evaluation of their effectiveness as a hydration factor when placed on a wound. The WVTR 236 
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recommended for wound dressing is 2000–2500 g/m2/day in order to ensure proper wound 237 
moisture without risk of dehydration or excessive production of exudates [1,4]. A good WVTR 238 
facilitates the healing process because it improves cell migration and promotes re-239 
epithelialization.  240 
The water loss from a fully hydrated dressing on exposure to air was evaluated. The mean 241 
evaporative water loss from PHHs was 2689.8 ± 158.5 g/m2/day. 242 
H2O2-producing activity  243 
All the honey samples, before inclusion in the membranes, were able to produce significant 244 
amounts of H2O2 while no H2O2 development was observed in the case of corresponding PHHs 245 
(data not shown). In Manuka honey, at shorter incubation times up to 90 min of incubation, the 246 
concentration of H2O2 generated by honey glucose oxidase was in the range reported in the 247 
literature for other types of honey with different methods of analyses (1–2 mM at 30 min of 248 
incubation) [16, 25-27]. By contrast, Manuka honey showed the lowest H2O2production at all 249 
incubation times, probably because of its high content of MGO, which has previously been 250 
suggested to be a glucose oxidase-inhibitory agent [16, 25]. At longer incubation times (24 and 251 
48 h), the tested honey samples displayed a significantly different behaviour: The dramatic loss 252 
of H2O2producing activity found for PHHs indicated that their production procedure, which 253 
included a heating step at 80 °C and exposure to γ-rays for final sterilization, induced complete 254 
loss of glucose oxidase activity. This demonstrated that the preserved antibacterial activity in the 255 
microbiological testing was generated solely by the action of nonperoxide agents. 256 
MGO analysis 257 
Dihydroxyacetone (DHA) is a direct precursor of MG in Manuka honey [15]. The MGO 258 
concentration in PHHs, determined by the N-acetyl-L-cysteine assay, was 0.26 ± 0.07 µmol/mg 259 
of proteins. The PHHs had higher MG concentration than bulk honey. MGO content is important 260 
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because it can serve as a suitable quality and cost parameter for Manuka honey. The H2O2 and 261 
MG content is responsible for the antibacterial activity of honey [28] and PHHs maintain 262 
antibacterial activity similar to that of bulk honey. 263 
Microbiological analysis 264 
Manuka membranes did not show bacterial contamination after sterilization by gamma-265 
irradiation. Table 1 outlines the antibacterial activity based on the clear zone that was produced.  266 
In vitro cytotoxicity assay  267 
Results concerning the effects induced by different concentrations of dissolved honey membrane 268 
on viability of L929 cells are represented in Figure 1.  269 
In vivo biocompatibility study 270 
Three rats from the treated group died of ascites in the first 24 hours. The gross evaluation in 36 271 
rats showed no wound site infection or presence of adhesions. On performing histological 272 
analysis 24 and 72 hours’ post-surgery, the tissue near the implant was found to be characterized 273 
by the presence of fibroblasts with some cellular response, including lymphocytes, macrophages, 274 
and neovascularisation. No reaction was observed in distant organs. Thus, the PHHs did not 275 
induce a foreign body reaction. The differences in the blood levels of the IL-1β, IL-6, TNF-α and 276 
PG(E2) at the 0, 6, 24, and 72 hours’ time points were not statistically significant. The results are 277 
summarized in Table 2.  278 
Discussion 279 
The new membranes may be used as wound dressings as they have a good WVTR and fluid 280 
uptake and show no cytotoxicity to fibroblasts; they also have good swelling capability, which is 281 
an important factor for reducing the risk of wound dehydration.  282 
 283 
 284 
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The results obtained by the citoxicity assay after 24 hours from the seeding, in presence of 285 
decreasing concentrations of dissolved honey membranes, have shown a statistically significant 286 
decrease (p<0.05) of the cells treated with the highest concentration (0.1 g/ml) compared to the 287 
control ones was observed. At 48 hours a trend in cell proliferation was found: highest 288 
concentrations seemed to induce a inhibition in cell growth while decreasing the concentration, 289 
the cell proliferation seemed to increase, even if it was not possible to highlight significant 290 
differences. Also at this time point it was possible to appreciate a statistically significant 291 
decreasing (p<0.05) of the cells treated with the highest concentration (0.1 g/ml) compared to the 292 
control.  293 
After 72 hours of incubation, the highest concentrations (from 1:2 to 1:64) caused an inhibition in 294 
cell growth while the lowest (1:256 and 1:512) induces a statistically significant increase in cell 295 
growth compared to the control. During the in vivo experiments, tree rats died: in authors’ 296 
opinion, this was because of the excessively large sheet of membrane implanted intraperitoneally 297 
because, initially, a dimension of 2 × 2 cm was chosen. Reducing the dimension of the implanted 298 
PHHs to 1 × 1 cm did not cause any intraperitoneal accumulation of fluid, as determined from 299 
macroscopic examination after euthanasia of the remaining rats. The tissue response to 300 
intraperitoneal and subcutaneous implants showed a similar macroscopic and histological pattern. 301 
In the light of PHHs antibacterial activity [12] and since administration of systemic antibiotics 302 
does not always lead to good outcomes in terms of: wound healing, matrix penetration of the EPS 303 
biofilm and antibiotic resistance, in this study we propose the use of Manuka honey to prepare 304 
PHH for wound dressings. Interestingly, our membranes demonstrate a good antibacterial activity 305 
toward clinically relevant pathogenic microorganisms such as S. aureus and E. coli. 306 
Honey membranes possess a wide variety of properties that can make them suitable (as for other 307 
natural materials such as chitosan hydrogels) [2, 24, 29], for very different uses that we can 308 
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hypothesise ranging from wound healing to adhesion prevention to drug delivery. The presence 309 
of natural active components, conformability, and complete resorbability are the main 310 
characteristics of this new biocompatible biomaterial that respects the pathophysiology of tissue, 311 
is well tolerated by the body, possibly improves healing, and may be used for the prevention of 312 
surgical complications. Furthermore, the production of these devices is extremely simple and 313 
inexpensive. 314 
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Figure 1: MTT assay (N=8) to evaluate the modulation of L292 cells growth after the treatment 401 
with decreasing concentrations of dissolved honey membrane in PBS at different experimental 402 
time points (24, 48, and 72 hours).  403 
